These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18473127)

  • 1. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.
    Okamura A; Yamamori M; Shimoyama M; Kawano Y; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Yakushijin K; Katayama Y; Sakaeda T; Hirai M; Matsui T
    Int J Hematol; 2008 Jul; 88(1):104-110. PubMed ID: 18473127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
    Kurata K; Yakushijin K; Okamura A; Yamamori M; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Kawamoto S; Matsuoka H; Murayama T; Minami H
    Cancer Chemother Pharmacol; 2018 May; 81(5):839-846. PubMed ID: 29511796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.
    Jenke A; Renner U; Richte M; Freiberg-Richter J; Platzbecker U; Helwig A; Thiede HM; Schäfer-Eckart K; Ehninger G; Bornhäuser M
    Clin Transplant; 2001 Jun; 15(3):176-84. PubMed ID: 11389708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Haentzschel I; Freiberg-Richter J; Platzbecker U; Kiani A; Schetelig J; Illmer T; Ehninger G; Schleyer E; Bornhäuser M
    Bone Marrow Transplant; 2008 Jul; 42(2):113-20. PubMed ID: 18362900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
    Jacobson P; El-Massah SF; Rogosheske J; Kerr A; Long-Boyle J; DeFor T; Jennissen C; Brunstein C; Wagner J; Tomblyn M; Weisdorf D
    Bone Marrow Transplant; 2009 Jul; 44(2):113-20. PubMed ID: 19151792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
    Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Lange S; Mueller SC; Altmann S; Dahlhaus M; Drewelow B; Freund M; Junghanss C
    Bone Marrow Transplant; 2008 Apr; 41(7):667-74. PubMed ID: 18084333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
    Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.